Similar articles

• Japan works to shorten "drug lag," boost trials of new drugs.

  Sinha G. Sinha G. J Natl Cancer Inst. 2010 Feb 3;102(3):148-51. doi: 10.1093/jnci/djq017. Epub 2010 Jan 27. J Natl Cancer Inst. 2010. PMID: 20107160 No abstract available.
• Slow start to phase 0 as researchers debate value.

  Twombly R. Twombly R. J Natl Cancer Inst. 2006 Jun 21;98(12):804-6. doi: 10.1093/jnci/djj249. J Natl Cancer Inst. 2006. PMID: 16788150 No abstract available.
• Can single-patient investigational new drug studies hurry slow trains to the fast track?

  Chenoweth D. Chenoweth D. Drug Discov Today. 2006 Mar;11(5-6):185-6. doi: 10.1016/S1359-6446(05)03707-4. Drug Discov Today. 2006. PMID: 16580594
• [Antitumor drug screening at the National Cancer Institute, U.S.A].

  Tsuruo T. Tsuruo T. Gan To Kagaku Ryoho. 1987 Oct;14(10):2809-15. Gan To Kagaku Ryoho. 1987. PMID: 3310904 Review. Japanese.
• Promising new agents under development by the Division of Cancer Treatment, Diagnosis, and Centers of the National Cancer Institute.

  Christian MC, Pluda JM, Ho PT, Arbuck SG, Murgo AJ, Sausville EA. Christian MC, et al. Semin Oncol. 1997 Apr;24(2):219-40. Semin Oncol. 1997. PMID: 9129691 Review.